A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Aspacytarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ayala Pharmaceuticals; BioSight
- 22 Nov 2022 According to a BioSight media release, first patient has been enrolled.
- 17 Aug 2022 Planned initiation date changed from 30 Aug 2022 to 17 Aug 2022.
- 17 Aug 2022 Status changed from not yet recruiting to recruiting.